Eisai hunts for next Alzheimer’s drug with new research pact

Eisai has agreed to a new deal with longtime Alzheimer’s disease partner BioArctic, signing up for a “research evaluation” of a preclinical drug designed to more effectively reach the brain. Announced Saturday, the agreement gives Eisai rights to license the drug, called BAN2802, after reviewing data from the collaboration.